# Inogen Inc: overview INGN · Nasdaq · CIK 1294133 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/ingn.md) · [Financials](/companies/ingn/financials.md) · [Filings](/companies/ingn/filings.md) · [Insiders](/companies/ingn/insiders.md) Latest reported revenue: [$83.5m](/filings/0001294133-26-000034.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 7, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001294133-26-000034). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [74.9](/filings/0001193125-25-269484.md) | [66.3 d](/filings/0001193125-26-082630.md) | [68.5](/filings/0001294133-26-000016.md) | [79.2](/filings/0001294133-26-000034.md) | [79.1](/filings/0001193125-25-269484.md) | [68.6 d](/filings/0001193125-26-082630.md) | [72.4](/filings/0001294133-26-000016.md) | [83.5](/filings/0001294133-26-000034.md) | | Gross margin | % | [55.2%](/filings/0001193125-25-269484.md) | [54.7% d](/filings/0001193125-26-082630.md) | [53.1%](/filings/0001294133-26-000016.md) | [52.2%](/filings/0001294133-26-000034.md) | [52.2%](/filings/0001193125-25-269484.md) | [51.4% d](/filings/0001193125-26-082630.md) | [52.3%](/filings/0001294133-26-000016.md) | [51.8%](/filings/0001294133-26-000034.md) | | Operating margin | % | [(10.4%)](/filings/0001193125-25-269484.md) | [(17.2%) d](/filings/0001193125-26-082630.md) | [(11.2%)](/filings/0001294133-26-000016.md) | [(7.7%)](/filings/0001294133-26-000034.md) | [(9.0%)](/filings/0001193125-25-269484.md) | [(13.6%) d](/filings/0001193125-26-082630.md) | [(12.9%)](/filings/0001294133-26-000016.md) | [(6.1%)](/filings/0001294133-26-000034.md) | | Net margin | % | [(8.0%)](/filings/0001193125-25-269484.md) | [(14.7%) d](/filings/0001193125-26-082630.md) | [(9.0%)](/filings/0001294133-26-000016.md) | [(5.2%)](/filings/0001294133-26-000034.md) | [(6.7%)](/filings/0001193125-25-269484.md) | [(10.4%) d](/filings/0001193125-26-082630.md) | [(11.5%)](/filings/0001294133-26-000016.md) | [(4.6%)](/filings/0001294133-26-000034.md) | | Diluted EPS | $ per share | [(0.25)](/filings/0001193125-25-269484.md) | not reported | [(0.25)](/filings/0001294133-26-000016.md) | [(0.15)](/filings/0001294133-26-000034.md) | [(0.20)](/filings/0001193125-25-269484.md) | not reported | [(0.30)](/filings/0001294133-26-000016.md) | [(0.14)](/filings/0001294133-26-000034.md) | | Free cash flow | $m | [5.3 d](/filings/0001193125-25-269484.md) | [(3.3) d](/filings/0001193125-26-082630.md) | [(17.1)](/filings/0001294133-26-000016.md) | [3.7 d](/filings/0001294133-26-000034.md) | [1.6 d](/filings/0001193125-25-269484.md) | [(1.9) d](/filings/0001193125-26-082630.md) | [(6.9)](/filings/0001294133-26-000016.md) | [2.2 d](/filings/0001294133-26-000034.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [312](/filings/0000950170-24-023820.md) | [321](/filings/0000950170-25-029993.md) | [252](/filings/0001193125-26-082630.md) | [279](/filings/0001193125-26-082630.md) | [295](/filings/0001193125-26-082630.md) | | Gross margin | % | [56.6%](/filings/0000950170-24-023820.md) | [47.9%](/filings/0000950170-25-029993.md) | [50.4%](/filings/0001193125-26-082630.md) | [55.5%](/filings/0001193125-26-082630.md) | [52.2%](/filings/0001193125-26-082630.md) | | Operating margin | % | [3.0%](/filings/0000950170-24-023820.md) | [(26.6%)](/filings/0000950170-25-029993.md) | [(43.5%)](/filings/0001193125-26-082630.md) | [(15.3%)](/filings/0001193125-26-082630.md) | [(10.2%)](/filings/0001193125-26-082630.md) | | Net margin | % | [(2.0%)](/filings/0000950170-24-023820.md) | [(26.1%)](/filings/0000950170-25-029993.md) | [(40.7%)](/filings/0001193125-26-082630.md) | [(12.9%)](/filings/0001193125-26-082630.md) | [(7.7%)](/filings/0001193125-26-082630.md) | | Diluted EPS | $ per share | [(0.28)](/filings/0000950170-24-023820.md) | [(3.67)](/filings/0000950170-25-029993.md) | [(4.42)](/filings/0001193125-26-082630.md) | [(1.52)](/filings/0001193125-26-082630.md) | [(0.86)](/filings/0001193125-26-082630.md) | | Free cash flow | $m | [18.2](/filings/0000950170-24-023820.md) | [(40.9)](/filings/0000950170-25-029993.md) | [(8.5)](/filings/0001193125-26-082630.md) | [2.6](/filings/0001193125-26-082630.md) | [(13.7)](/filings/0001193125-26-082630.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ingn/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $11.3m | 1,748,986 | | Added +101,902 | | [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $7.1m | 1,096,000 | | Reduced −104,000 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $6.7m | 1,038,316 | | Added +1,611 | | [AMERIPRISE FINANCIAL INC](/funds/820027.md) | 2026-06-30 | $6.3m | 983,028 | | Added +123,485 | | [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $6.0m | 937,334 | | Added +510,216 | | [DAFNA Capital Management LLC](/funds/1389933.md) | 2026-06-30 | $5.5m | 845,179 | | Unchanged | | [ARROWSTREET CAPITAL, LIMITED PARTNERSHIP](/funds/1164508.md) | 2026-06-30 | $4.8m | 743,252 | | Added +157,093 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $4.2m | 646,276 | | Added +105,111 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $4.1m | 641,521 | | Added +27,992 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $3.8m | 591,943 | | Added +18,739 | ## Recent filings [All 990 filings](/companies/ingn/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-30 | 16:10 ET | [8-K](/filings/0001294133-26-000037.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001294133-26-000037 | | 2026-08-07 | 16:11 ET | [10-Q](/filings/0001294133-26-000034.md) | Quarterly report, period 2026-06-30 | 0001294133-26-000034 | | 2026-08-06 | 16:10 ET | [8-K](/filings/0001294133-26-000032.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001294133-26-000032 | | 2026-07-01 | 16:09 ET | [8-K](/filings/0001294133-26-000025.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001294133-26-000025 | | 2026-06-11 | 16:32 ET | [8-K](/filings/0001294133-26-000021.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001294133-26-000021 | | 2026-05-08 | 16:10 ET | [10-Q](/filings/0001294133-26-000016.md) | Quarterly report, period 2026-03-31 | 0001294133-26-000016 | | 2026-05-07 | 16:13 ET | [8-K](/filings/0001294133-26-000014.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001294133-26-000014 | | 2026-04-28 | 16:09 ET | [DEF 14A](/filings/0001294133-26-000009.md) | Proxy statement, period 2026-04-28 | 0001294133-26-000009 | | 2026-04-06 | 16:02 ET | [8-K](/filings/0001193125-26-143703.md) | 1.01 Entry into a material agreement; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-143703 | | 2026-03-30 | 17:32 ET | [8-K](/filings/0001193125-26-131855.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-131855 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-082630.md), filed Feb 27, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/320d9ca6-1d8a-4f2b-b1ca-e9b96e266e62) ## About the filer - CIK: 1294133 - Tickers: INGN - Exchange: Nasdaq - SIC code: 3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies - State of incorporation: DE - Filer category: Accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:36 ET. No prices; not investment advice.